pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Immunology · news · pharmadog
← back to Immunology
News mentioning Immunology
183
stories
14h
Lilly doubles down on Gate alliance to unlock new drug class with another $870M+ in biobucks
biospace
15h
CSL strikes up to $1.6B deal with Alentis for autoimmune drug with broad potential
biospace
15h
Biogen’s big lupus bet gets boost from new durability data for skin disease
biospace
1d
Roivant, the 'inveterate drug hunters', enters commercial era with Lisraya
biospace
3d
BMO most bullish on Merck's, bearish on BMS’ plans to contend with patent cliffs
biospace
3d
Foghorn cuts 40% of workforce
biospace
3d
‘We’ve been taking our time’: Buzzy AI biotech Xaira reveals antibody platform, first taste of pipeline
fiercebiotech
4d
Sanofi, Regeneron broaden alliance to find their next Dupixent
biopharma dive
4d
Merck’s antibody impresses with ‘highly competitive’ data in chronic skin disease
biospace
4d
Pfizer’s eczema drug clears skin in mid-stage trial
biopharma dive
4d
Foghorn lays off 40% of staff after Lilly collaboration ends
biospace
4d
Sanofi pays Regeneron $1B upfront to continue search for Dupixent successor
biospace
4d
STAT+: Why a Huntington’s patient isn’t fazed by the waning effect of UniQure’s gene therapy
stat
4d
STAT+: Invivyd’s pursuit of a Covid vaccine alternative gets a lift, but an FDA hurdle may await
stat
4d
Sanofi builds on immunology alliance with Regeneron for $1B upfront
endpoints
4d
Foghorn lays off 40% of employees as Lilly cancer collab collapses over poor data
fiercebiotech
4d
STAT+: Sanofi, Regeneron expand partnership after Dupixent success
stat
5d
Sanofi pays Dupixent partner Regeneron $1B upfront for 4 early-stage assets to ignite R&D
fiercebiotech
6d
Biopharma needs to reward scientists' judgment
biospace
6d
Biopharma needs to reward scientists' judgment
biospace
6d
Enanta sheds staffers as key antiviral, immunology readouts loom
fiercebiotech
6d
ai3Bio, built from two biotechs, pursues a different path to an ‘immune reset’
biopharma dive
7d
Novo agrees $2.6B deal for preclinical GLP-1/GIP drug from in-demand Hengrui
fiercebiotech
7d
‘We’re so close to the tech companies’: Genentech CEO talks Fierce through vision for the future
fiercebiotech
7d
Tolerance continues thymus-focused deals with $560M pact for Tanabe's clinical-stage IL-33 drug
fiercebiotech
7d
Opinion: AI is eroding the barriers that kept biological weapons rare
stat
7d
STAT+: Once described as obesity medicines for ‘patients,’ GLP-1s are increasingly lifestyle drugs for ‘customers’
stat
8d
6 immunology targets to sustain a mammoth I&I market
biospace
10d
STAT+: Lilly wins approval for once-weekly insulin shot
stat
10d
Nektar prevails in legal battle with Lilly over broken rezpeg partnership
biospace
← prev
page 1 of 7
next →
